MedTrace Logo

TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)

NCT01242696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1014

Last updated 2017-02-03

No results posted yet for this study

Summary

The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice.

Conditions

Interventions

PROCEDURE

Coronary artery stenting

Coronary artery stenting with drug eluting stents

Sponsors & Collaborators

  • Pharmaceutical Research Associates

    collaborator OTHER

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Corrado Tamburino, Prof. · Ospedale Ferrarotto, Via Citelli, 1, 95100 Catania, Italy

  • Peter Maurer, PhD · Boston Scientific Corporation

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-03-31
Completion
2015-07-31

Countries

  • Belgium
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242696 on ClinicalTrials.gov